Celltrion, Inc. Logo

Celltrion, Inc.

A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.

068270 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
인천광역시 연수구 아카데미로 23, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celltrion, Inc. is a leading global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative therapeutics. A pioneer in the biosimilar field, Celltrion launched the world's first monoclonal antibody biosimilar and continues to be a market leader. The company's portfolio includes a range of biosimilars and novel drugs targeting therapeutic areas such as immunology, oncology, hematology, and endocrinology. Celltrion provides comprehensive, end-to-end solutions across the biopharmaceutical value chain, from R&D and clinical trials to production and sales, with a commitment to improving worldwide patient access to high-quality, affordable medicines.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Celltrion, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 724.1 KB
2025-09-17 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 33.3 KB
2025-09-08 00:00
Related Party Transaction
임원ㆍ주요주주특정증권등거래계획보고서
Korean 70.7 KB
2025-09-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.0 KB
2025-09-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-09-01 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 승인(Part2))
Korean 12.2 KB
2025-09-01 00:00
Major Shareholding Notification
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 31.0 KB
2025-08-27 00:00
Regulatory News Service
풍문또는보도에대한해명(미확정)
Korean 7.9 KB
2025-08-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB

Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan 9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan 4967
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884

Talk to a Data Expert

Have a question? We'll get back to you promptly.